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Background: Propionic acid (PA) found in some foods and formed as a metabolic product of gut bacteria has been
reported to mimic/mediate the effects of autism. The present study was undertaken to compare the effect of orally
administered PA with that of clindamycin-induced PA-microbial producers in inducing persistent biochemical autistic
features in hamsters. The neuroprotective potency of carnosine and carnitine supplements against PA toxicity was also
investigated.
Methods: The following groups were studied. 1. Control group, which received phosphate buffered saline orally,
2. Propionic acid treated group which were given PA at a dose of 250 mg/kg body weight/day for 3 days orally,
3. Clindamycin treated group which received a single dose of the antibiotic orogastrically at a dose of 30 mg/kg
on the day of the experiment, 4. Carnosine-treated group which were given carnosine at a dose of 10 mg/kg
body weight/day orally for one week, 5. Carnitine treated group given 50 mg/kg body weight/day carnitine orally daily
for one week. Group 6. Carnosine followed by PA, Group 7. Carnitine followed by PA. Dopamine, adrenaline and
noradrenaline, serotonin and Gamma amino-butyric acid (GABA) were measured in the cortex and medulla of
the nine studied groups.
Results: PA administration caused significant decrease in the neurotransmitters in the brains of treated
hamsters while clindamycin caused a significant decrease only in dopamine in hamster brains (cortex and
medulla) and GABA in the cerebral cortex of the treated hamsters. Administration of carnosine and carnitine
which are known antioxidants caused no significant changes in the levels of neurotransmitters when
administered alone to hamsters. However when administered with PA both carnosine and carnitine restored the
altered neurotransmitters to near normal levels.
Conclusion: Carnosine and carnitine may be used as supplements to protect against PA neurotoxicity.
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Propionic acid (PA) occurs naturally in a few food prod-
ucts; for example PA is present in low quantities in milk
and relatively higher levels in dairy products such as
yogurt and cheese, obviously due to bacterial fermenta-
tion, mostly by propionibacteria [1,2]. The food sources
however have a minor contribution in the PA levels in
the body [3]. In the colon, PA is produced by fermentation* Correspondence: elansary@ksu.edu.sa
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stated.of polysaccharides, oligosaccharides, long-chain fatty
acids, protein, peptides and glycoprotein precursors by
the anaerobic colonic microbiota, although in quanti-
tative terms undigested carbohydrates, such as dietary
fibers and resistant starch, represent the major source
for PA production [3,4].
PA is a short chain fatty acid formed endogenously in
the human body as an intermidiate of fatty acid metabol-
ism and a metabolic end product of enteric gut bacteria
such as clostridia and propionibacteria [3,5-7]. Recent
studies of El-Ansary et al. [8] have demonstrated that PA
administration to rats caused an increased generation ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
El-Ansary et al. Gut Pathogens 2013, 5:32 Page 2 of 6
http://www.gutpathogens.com/content/5/1/32oxidative stress which was accompanied by impairment
of antioxidant defense indices.
Autism is a disorder of neural development which in-
cludes development deficiencies of language and social
interaction skills, appearance of repetitive and disordered
movements [9] hyperactivity, sensory disturbances, re-
stricted interests and sometimes self injury [10,11]. Intra-
ventricular infusions of PA have been shown to cause
behavioral and brain abnormalities in rats similar to those
seen in humans suffering from autism [12-14]. Gut mi-
crobes have long been suspected to play a role in autism
spectrum disorders (ASD) [15]. Gut microbiota also play
an important role in metabolism of xenobiotics, modifica-
tion of drugs etc., [16]. Clindamycin has been shown to
cause loss of majority of normal caecal flora and induction
of PA producing bacteria among which is Clostridia spe-
cies [17]. In this study hamsters were treated with the
antibiotic clindamycin to see if its effects were similar to
that of exogenous PA which has been implicated in aut-
ism. Attempts were also made to understand the neuro-
chemical effects of PA and induced PA production either
alone or in combination with carnosine, carnitine as po-
tent antioxidants.Material and methods
Chemicals
Propionic acid, carnosine and carnitine were of analyt-
ical grade products of Sigma-Aldrich.
Clindamycin (Cleocin phosphate) was obtained from
Pharmacia Co.,Peapack, NJ, USA).Animals
A total of 54 young male golden Syrian hamsters weigh-
ing about 80–100 grams were used in the present study.
Animals were randomly into seven groups, each consist-
ing of 6 animals. The groups studied included 1. Control
group, which received phosphate buffered saline orally,
2. Propionic acid treated group which were given PA at
a dose of 250 mg/Kg body weight/day for 3 days orally
[18], 3. Clindamycin treated group which received a sin-
gle dose of the antibiotic orogastrically at a dose of
30 mg/kg on the day of the experiment, 4. Carnosine-
treated group were given carnosine at a dose of 10 mg/kg
body weight/day orally for one week, 5. Carnitine treated
group were given 50 mg/kg body weight/day carnitine or-
ally daily for one week. The protected groups included
Group 6. Carnosine followed by PA, Group 7. Carnitine
followed by PA. The carnosine and carnitine protected
group were given the same doses of the respective com-
pounds for one week followed by PA for three days. All
the groups were kept at controlled temperature (21 ± 1°C)
with ad libtium access to food and water. The experiments
were performed in accordance with national animal careguidelines approved by the Animal Ethics Committee,
King Saud University, Riyadh.
Brain tissue preparation
At the end of experiment, hamsters were killed by car-
bon dioxide asphyxiation. The brains were dissected out
and washed in saline. Cortex and medulla were sepa-
rated. The tissues were homogenized in double distilled
water and the homogenates were stored at −80°C until
used.
Catecholamines assay
Dopamine, adrenaline and noradrenaline were extracted
from rat brain by using a cis-diol-specific affinity gel, ac-
ylated and then derivatized enzymatically. Quantitavive
assay of the three neurotransmitters were performed
using ELISA kit, a product of Immuno Biological La-
boratories (IBL) using dopamine, adrenaline and nor-
adrenaline antiserum provided. Sensitivities for adrenalin
of 0.3 ng/mL, for noradrenaline of 0.6 ng/mL and for
dopamine of 5 ng/mL for diluted sample were recorded.
Assay of serotonin
Serotonin was measured using an ELISA kit, a product of
Immunology Biological Laboratories (IBL). Brain hom-
ogenate (derivatization of serotonin to N-acylserotonin)
was done by sample dilution and incubation of the respect-
ive sample with the acylation reagent. The assay procedure
followed the basic principle of competitive ELISA whereby
there is competition between a biotinylated and a non-
biotinylated antigen for a fixed number of antibody binding
sites. The amount of biotinylated antigen bound to the
antibody is inversely proportional to the N-acylserotonin
concentration of the sample. When the system is in equi-
librium, the free biotinylated antigen is removed by a wash-
ing step and the antibody bound biotinylated antigen is
determined by use of anti-biotin alkaline phosphatase as
marker and p-nitrophenyl phosphate as substrate. Quanti-
fication of unknowns was achieved by comparing the en-
zymatic activity of samples with a response curve prepared
by using known standards.
Assay of gamma amino-butyric acid (GABA)
Quantitative determination of GABA was done using
ELISA immunoassay kit, a product of ALPCO. 300 μL of
diluted standards, controls and undiluted samples were
placed into the appropriate wells of the extraction plate.
300 μL of the diluent was added to all wells, covered
with adhesive foil and shook for 30 min at room
temperature (20-25°C) on a shaker (600 rpm). Two
washing cycles were performed, after which 250 μl elu-
tion buffer was placed into the appropriate wells of the
extraction plate, covered and shook followed by addition
of 100 μL of the extract for subsequent derivatization.
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50 μL of the equalizing reagent (fresh prepared before
assay) and shook for 1 min on a shaker (600 rpm). 10 μL
of the D-reagent was added into all wells, incubated for
2 hours at (20-25°C) and then 150 μL Q-buffer was added
into all wells, incubated for 10 min at RT (20-25°C) on a
shaker (approx. 600 rpm). 25 μL of the derivative was used
for the subsequent ELISA.
Statistical analysis
A computer SPSS program was used, and the results
were expressed as mean ± SD (n = 6). Comparisons were
made by the one-way ANOVA between the control and
treated groups. Dunnett’s test was used to compare be-
tween the groups. Receiver operating characteristic (ROC)
analysis was done. Area under the curve, specificity and
sensitivity were calculated.
Results and discussion
Autism spectrum disorders (ASD) comprise a complex
and heterogeneous group of conditions that include aut-
ism, Rett and Asperger syndromes, and pervasive develop-
mental disorder-otherwise non specified [19]. The main
clinical features of ASD are stereotypic behaviors and
marked impairment in communication, social skills and
cognition [20,21]. Animal models help us understand the
mechanism of disease process and the environmental fac-
tors which serve as trigger for the disease process. Studies
of MacFabe et al. [12] have demonstrated PA injection in
rats provides a suitable animal model to study ASD.
Moreover, there are a series of inherited and acquired con-
ditions which lead to elevations of PA and other short
chain fatty acids and these are related to developmental
delay, seizures and gastrointestinal symptoms, resembling
some aspects of autism [22,23]. Thus, PA may be a pu-





























Figure 1 Effect of propionic acid, antibiotic clindamycin, carnosine, ca
in the cerebral cortex of hamsters. Concentrations of various neurotransmetabolites along with genetic predisposition and sub-
sequent features of autism [8].
Figure 1 shows the effect of PA, antibiotic clindamycin,
carnosine, carnitine alone and with PA on the neuro-
transmitter levels in the cerebral cortex of hamsters. Ad-
ministration of PA alone caused a significant decrease in
the levels of neurotransmitters viz., adrenalin, noradren-
alin, serotonin, dopamine and GABA by 53, 44, 22, 25
and 64% respectively when compared to the control
group (P <0.05). This is in accordance with the earlier
report of El-Ansary et al. [8] where a significant decrease
in neurotransmitters was observed in rats treated with
PA. The decrease in the levels of neurotransmitters may
be due to affect of PA on the transcription of the tyro-
sine hydroxylase gene encoding the rate-limiting enzyme
in the biosynthesis of the neurotransmitters dopamine,
norepinephrine and epinephrine. Short chain fatty acids
like butyrate are known to alter tyrosine hydroxylase
gene expression [24]. Norepinephrine (also known as
noradrenaline) is a catecholamine that is synthesized
from dopamine through the action of the enzyme dopa-
mine beta-hydroxylase [25]. Noradrenergic activity has
been assessed in autism via measurement of norepineph-
rine (NE) and its central and/or peripheral metabolites
in blood, urine, and CSF [25]. Various studies suggest lit-
tle role for NE in the expression and etiology of autistic
disorder [25]. In the present study PA decreased the
levels of adrenalin and norepinephrine in hamster brains
while carnosine/carnitine with PA showed a tendency
towards restoration to normal levels.
Antibiotics are commonly used pharmaceuticals. While
most of them are well tolerated, they do have side effects
the most common being diarrhea. The neurotoxic effects
of antibiotics are not well recognized [26]. Therefore there
are chances of neurotoxic effects of antibiotics being con-
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to markedly suppress the anaerobic microbial community
including members of the Bacteroides group, which ac-
count for ∼ 30% of the intestinal bacterial flora [2,27,28].
The change in the intestinal flora may interfere with intes-
tinal enzyme DPP-IV (dipeptydal peptidase), which cata-
lyzes the breakdown of proteins into amino acids, and has
been hypothesized as a contributing factor to autism [29].
This is due to the fact that this enzyme is necessary to
breakdown peptides into amino acids which are precur-
sors of neurotransmitters.
Though clindamycin is not known have major neuro-
toxic effects [26] in the present study treatment of ham-
sters with antibiotic alone caused a significant decrease in
dopamine by 15% (P >0.05) and GABA by 16% (P <0.05)
in the cortex when compared to the cerebral cortex of
control group of rats. Though the exact cause of decrease
of these neurotransmitters is not known, it may be due to
inhibition of monoamine oxidase [30]. Carnosine is a an
antioxidant dipeptide consisting of amino acids histidine
and alanine. L-Carnosine is a highly effective anti-aging
nutrient that it possesses powerful antioxidant, free radical
scavenging and neurotransmitter properties. Carnosine in-
hibits the formation of carbonyl groups, thereby reducing
the formation of abnormal proteins. L-Carnosine extends
maximum cell division capacity, protects against DNA
oxidation, blocks glycosylation and reduces Advanced
Glycation Endproducts, as well as acts as a cell membrane
stabilizer and an intracellular buffer [31]. L-Carnosine has
recently been shown to possess a tremendous potential
for improving language and behavior in children diag-
nosed with ASDs [31]. In the present study carnosine
treatment caused no significant change in the levels of
neurotransmitters studied (P >0.05). Similarly carnitine






























Figure 2 Effect of propionic acid, antibiotic clindamycin, carnosine, ca
in the medulla of hamsters. Concentrations of various neurotransmittersof neurotransmitters studied (P >0.05). Earlier studies
[32,33] have found that acetyl-L-carnitine treatment in-
creases noradrenalin and serotonin levels in brains of
treated mice. This was accompanied by decrease in the
levels of GABA in the brains of treated mice [33]. Co ad-
ministration of propionic acid and carnosine to hamsters
caused an increase in adrenalin by 60% (P <0.05), dopa-
mine by 8% (P <0.05) and in GABA by 35% (P <0.01)
when compared to the group treated with propionic acid
alone in the cortex of treated hamsters.
Treatment of propionic acid and carnitine also caused
an increase in adrenalin by 23% (P < 0.01), noradrenalin
by 20% (P < 0.01), dopamine by 7% (P <0.05) and GABA
by 120% (P <0.01) when compared to the group treated
with propionic acid alone.
Figure 2 shows the effect of propionic acid, antibiotic
clindamycin, carnosine, carnitine alone and with propio-
nic acid on the neurotransmitter levels in the cerebral
medulla of hamsters. Treatment of hamsters with
propionic acid caused a decrease in adrenalin by 45%
(P <0.05), noradrenalin by 38% (P <0.05), serotonin by
33% (P <0.05), dopamine by 32% (P <0.01) and GABA
by 54% (P <0.01) when compared to cerebral medulla
of control group. This may be due to the effect of PA
on tyrosine hydroxylase [24]. Glutamate and gamma-
aminobutyric acid (GABA) are the two neurotransmitters
that are linked to widespread synaptic communication in
the central nervous system [25]. Glutamate is the principal
excitatory neurotransmitter in the brain and spinal cord,
whereas GABA is responsible for most of the inhibitory
communication in the brain [34,35]. These substances are
widely produced in the central nervous system by the
cells’ metabolic processes, and their effects are wide-
spread. There are few areas in the brain that do not re-
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GABA is converted from glutamate by the enzyme glu-
tamic acid decarboxylase (GAD). GAD is the rate-limiting
step of the synthesis of GABA [25]. Fatemi et al., 2008
found that this enzyme was reduced by 48–61% in parietal
and cerebellar areas of brains of individuals with autism
when compared to controls [36]. These differences were
statistically significant, and provide an insight into the ab-
normal levels of GABA in brain during autism. Administra-
tion of antibiotic clindamycin to hamsters caused significant
decrease only in dopamine levels by 18% (P <0.05) when
compared to control hamsters medulla. This effect is parallel
to the effect of PA on hamster cortex. As in the case of cor-
tex, carnosine and carnitine treatments alone to hamsters
caused no significant change in the levels of any of neuro-
transmitters (P >0.05). Propionic acid treatment along with
carnosine caused significant increases in the levels of adren-
alin by 22% (P <0.01), noradrenalin by 22% (P <0.05), dopa-
mine by 22% (P <0.05) and GABA by 24% (P <0.01) when
compared to that in the medulla of propionic acid treated
hamsters. Propionic acid and carnitine treatment to ham-
sters caused an increase in adrenalin by 32% (P <0.01), nor-
adrenalin by 3% (P <0.05), dopamine by 15% (P <0.05) and a
decrease in serotonin by 5% (P <0.05) when compared to
the group of hamsters treated with propionic acid alone.
Our earlier studies have also demonstrated the toxic effect
of PA through DNA damage and the protective effects of
carnosine and carnitine on PA induced DNA damage [37].
ROC analysis showed satisfactory values of area under
the curve, sensitivity and specificity. This helps to sug-
gest that the measured neurotransmitters could be used
as biomarkers for PA and bacterial overgrowth neuro-
toxicity and as predictive markers to follow the efficacy
of both carnosine and carnitine in ameliorating the toxic
effects related to PA.
Conclusion
The results of the present study lead us to speculate that
PA may play a role in ASD by interfering with the neuro-
transmitters. Carnosine and carnitine which are known
antioxidants cause no significant changes in the levels of
neurotransmitters when administered alone to hamsters.
However when administered with PA both carnosine and
carnitine tended to restore the altered levels of neuro-
transmitters to near normal levels. Therefore carnosine
and carnitine may be used as antioxidants as supplements
to protect against PA neurotoxicity.
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